Clinical Trial Update: Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pirfenidone for reducing metabolic, inflammatory, and fibrogenic activity in complicated silicosis with progressive massive fibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complicated Silicosis
• Progressive Massive Fibrosis
• Silicosis

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Instituto de investigación e innovación biomédica de Cádiz | Conditions: Silicosis, Progressive Massive Fibrosis | Phase 2 | Status: UNKNOWN